Compare Duolingo Inc (DUOL) vs Novavax Inc (NVAX) Price & Performance

Duolingo trades at $131.94, down 3.83% amid mixed signals. The stock shows strong fundamentals with revenue growing from $369M in 2022 to $1.04B in 2025 and net income turning positive to $414M. Technical indicators show a bullish moving average trend but neutral oscillators, with key support at $129. Recent Q2 2026 earnings beat expectations with $0.66 EPS versus $0.604 expected, though Q3 revenue guidance disappointed investors.

The outlook remains cautiously optimistic with 30% analyst buy ratings but significant execution risk. Growth investments pressure near-term margins while user engagement strengthens. Key risks include monetization challenges and competitive threats in the edtech space. The consensus price target of $121 suggests limited upside from current levels.

NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.

The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.